PharmacyCodes



Oxaloplatine [French] en es it fr

Categorie

Oxaloplatine [French] Les marques, Oxaloplatine [French] Analogs

Oxaloplatine [French] Les marques melange

  • No information avaliable

    • Oxaloplatine [French] Formule chimique

    C8H12N2O4Pt

    Oxaloplatine [French] RX lien

    http://www.rxlist.com/cgi/generic/eloxatin.htm

    Oxaloplatine [French] FDA fiche

    Oxaloplatine_[French] FDA

    Oxaloplatine [French] msds (fiche de securite des materiaux)

    Oxaloplatine_[French] MSDS

    Oxaloplatine [French] Synthese de reference

    Aucune information disponible

    Oxaloplatine [French] Poids moleculaire

    395.27 g/mol

    Oxaloplatine [French] Point de fusion

    No information avaliable

    Oxaloplatine [French] H2O Solubilite

    Aucune information disponible

    Oxaloplatine [French] Etat

    Solid

    Oxaloplatine [French] LogP

    No information avaliable

    Oxaloplatine [French] Formes pharmaceutiques

    Aucune information disponible

    Oxaloplatine [French] Indication

    Pour le traitement des tumeurs malignes du côlon, du rectum, et de l'ovaire

    Oxaloplatine [French] Pharmacologie

    L'oxaliplatine inhibe sélectivement la synthèse de l'acide désoxyribonucléique (ADN). Le contenu guanine et la cytosine est corrélée avec le degré d'oxaliplatine induit une réticulation. A des concentrations élevées de la drogue, de l'ARN cellulaire et la synthèse des protéines sont également supprimées.

    Oxaloplatine [French] Absorption

    Aucune information disponible

    Oxaloplatine [French] Toxicite

    Aucune information disponible

    Oxaloplatine [French] Information pour les patients

    Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.

    Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.

    Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

    Oxaloplatine [French] Organismes affectes

    Les humains et autres mammifères